Aldeyra Therapeutics, Inc. (ALDX) Cash Flow Statement
Aldeyra Therapeutics, Inc. (ALDX) generated -$22.0M of operating cash flow over the twelve months to 2026-06-30, spent $23097 on capital expenditure and had free cash flow of -$22.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALDXAldeyra Therapeutics, Inc.Follow ALDX — free
—
Price chart with a free account
- Market cap
- 39.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.8 | -9.3 | -15.1 | -19.2 | -29.9 | -45.0 | -37.5 | -42.6 | -56.6 | -30.3 | -43.2 | -33.3 | -22.0 | |
| Capital expenditure | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 | 0.0 | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -4.8 | -9.4 | -15.2 | -19.2 | -30.1 | -45.0 | — | -42.6 | -56.7 | -30.3 | -43.2 | -33.3 | -22.0 | |
| Stock-based compensation | 2.0 | 2.2 | 2.8 | 2.7 | 4.1 | 8.1 | 7.1 | 7.1 | 8.3 | 5.8 | 8.0 | 6.1 | — |
USD millions · SEC XBRL
Aldeyra Therapeutics, Inc. — questions
- What is Aldeyra Therapeutics, Inc.'s operating cash flow?
- -$22.0M over the twelve months to 2026-06-30.
- How much does Aldeyra Therapeutics, Inc. spend on capital expenditure?
- $23097 over the twelve months to 2026-06-30.
- What is Aldeyra Therapeutics, Inc.'s free cash flow?
- -$22.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Aldeyra Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.